Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/32990
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
Metadata
Show full item record
BCG VACCINATION FOLLOWING LATENT TB TREATMENT: POSSIBLE IMPLICATIONS FOR DIFFERENT SETTINGS
Author
Affilliation
University College London. Institute for Global Health. UK.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
University College London. Institute for Global Health. UK.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
London School of Hygiene and Tropical Medicine. UK.
University College London. Institute for Global Health. UK.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
University College London. Institute for Global Health. UK.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
London School of Hygiene and Tropical Medicine. UK.
University College London. Institute for Global Health. UK.
Abstract
Despite much progress globally, TB is still one of the top 10 causes of death worldwide. Several studies have shown the importance of implementing different preventive strategies alongside treatment of TB disease, including BCG vaccination and treatment of latent tuberculosis infection (LTBI). Large-scale population level LTBI treatment is not currently part of WHO guidelines which recommend LTBI treatment only to high risk populations. Moreover, BCG has been widely used in the past decades to both prevent infection with M. tuberculosis and reduce rates of reactivation. In this viewpoint we discuss the hypothesis of BCG vaccination following latent TB treatment and its potential impact across different settings.
Share